DrugDashboards

Emend

Fosaprepitant Dimeglumine · FOSAPREPITANT DIMEGLUMINE 150 mg/5mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Merck Sharp & Dohme LLC

NDC 00006-3061-00 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$0.1230per billing unit (1 MG)HCPCS J1453 · Jul 1, 2026
  • Part D plans paid (avg)$253.51per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal ceiling (Big4)$195.37per package of 150MGMerck Sharp & Dohme LLC · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$334.63
Reported to Texas DSHS · 2026 annual filing · Merck Sharp & Dohme LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$0.123
HCPCS J1453 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$355,215
3,816 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $2,508.20 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA022023
TE code
AP
Approval date
Jan 25, 2008
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Fosaprepitant Dimeglumine (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Avenacy, LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
BluePoint LaboratoriesFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Eugia US LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Merck Sharp & Dohme LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
NorthStar RxLLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Qilu Pharmaceutical Co., Ltd.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 1, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Emend — NDC 00006-3061-00," retrieved September 3, 2026, https://drugdashboards.com/drug/00006306100.

Free to cite with attribution — see how the data is put together.